OL-FS13 Alleviates Cerebral Ischemia-reperfusion Injury by Inhibiting miR-21-3p Expression.

Naixin Liu, Yan Fan, Yilin Li, Yingxuan Zhang, Jiayi Li, Yinglei Wang, Zhuo Wang, Yixiang Liu, Yuansheng Li, Zijian Kang, Ying Peng, Zeqiong Ru, Meifeng Yang, Chengan Feng, Ying Wang, Xinwang Yang
Author Information
  1. Naixin Liu: Department of Anatomy and Histology & Embryology, Faculty of Basic Medical Science, Kunming Medical University, Kunming, 650500, Yunnan, China.
  2. Yan Fan: Department of Anatomy and Histology & Embryology, Faculty of Basic Medical Science, Kunming Medical University, Kunming, 650500, Yunnan, China.
  3. Yilin Li: Department of Anatomy and Histology & Embryology, Faculty of Basic Medical Science, Kunming Medical University, Kunming, 650500, Yunnan, China.
  4. Yingxuan Zhang: Department of Anatomy and Histology & Embryology, Faculty of Basic Medical Science, Kunming Medical University, Kunming, 650500, Yunnan, China.
  5. Jiayi Li: Department of Anatomy and Histology & Embryology, Faculty of Basic Medical Science, Kunming Medical University, Kunming, 650500, Yunnan, China.
  6. Yinglei Wang: Department of Anatomy and Histology & Embryology, Faculty of Basic Medical Science, Kunming Medical University, Kunming, 650500, Yunnan, China.
  7. Zhuo Wang: Department of Anatomy and Histology & Embryology, Faculty of Basic Medical Science, Kunming Medical University, Kunming, 650500, Yunnan, China.
  8. Yixiang Liu: Key Laboratory of Chemistry in Ethnic Medicinal Resources & Key Laboratory of Natural Products Synthetic Biology of Ethnic Medicinal Endophytes, School of Ethnic Medicine, Yunnan Minzu University, State Ethnic Affairs Commission & Ministry of Education, Kunming, Yunnan, 650504, China.
  9. Yuansheng Li: Department of Anatomy and Histology & Embryology, Faculty of Basic Medical Science, Kunming Medical University, Kunming, 650500, Yunnan, China.
  10. Zijian Kang: Department of Anatomy and Histology & Embryology, Faculty of Basic Medical Science, Kunming Medical University, Kunming, 650500, Yunnan, China.
  11. Ying Peng: Department of Anatomy and Histology & Embryology, Faculty of Basic Medical Science, Kunming Medical University, Kunming, 650500, Yunnan, China.
  12. Zeqiong Ru: Department of Anatomy and Histology & Embryology, Faculty of Basic Medical Science, Kunming Medical University, Kunming, 650500, Yunnan, China.
  13. Meifeng Yang: Department of Anatomy and Histology & Embryology, Faculty of Basic Medical Science, Kunming Medical University, Kunming, 650500, Yunnan, China.
  14. Chengan Feng: Department of Anatomy and Histology & Embryology, Faculty of Basic Medical Science, Kunming Medical University, Kunming, 650500, Yunnan, China.
  15. Ying Wang: Key Laboratory of Chemistry in Ethnic Medicinal Resources & Key Laboratory of Natural Products Synthetic Biology of Ethnic Medicinal Endophytes, School of Ethnic Medicine, Yunnan Minzu University, State Ethnic Affairs Commission & Ministry of Education, Kunming, Yunnan, 650504, China.
  16. Xinwang Yang: Department of Anatomy and Histology & Embryology, Faculty of Basic Medical Science, Kunming Medical University, Kunming, 650500, Yunnan, China.

Abstract

BACKGROUND: OL-FS13, a neuroprotective peptide derived from Odorrana livida, can alleviate cerebral ischemia-reperfusion (CI/R) injury, although the specific underlying mechanism remains to be further explored.
OBJECTIVE: The effect of miR-21-3p on the neural-protective effects of OL-FS13 was examined.
METHODS: In this study, the multiple genome sequencing analysis, double luciferase experiment, RT-qPCR, and Western blotting were used to explore the mechanism of OL-FS13.
RESULTS: Showed that over-expression of miR-21-3p against the protective effects of OL-FS13 on oxygen- glucose deprivation/re-oxygenation (OGD/R)-damaged pheochromocytoma (PC12) cells and in CI/R-injured rats. miR-21-3p was then found to target calcium/calmodulin-dependent protein kinase 2 (CAMKK2), and its overexpression inhibited the expression of CAMKK2 and phosphorylation of its downstream adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK), thereby inhibiting the therapeutic effects of OL-FS13 on OGD/R and CI/R. Inhibition of CAMKK2 also antagonized up-regulated of nuclear factor erythroid 2-related factor 2 (Nrf-2) by OL-FS13, thereby abolishing the antioxidant activity of the peptide.
CONCLUSION: Our results showed that OL-FS13 alleviated OGD/R and CI/R by inhibiting miR-21-3p to activate the CAMKK2/AMPK/Nrf-2 axis.

Keywords

References

  1. Dis Markers. 2021 Oct 22;2021:4409212 [PMID: 34721735]
  2. Brain Res Rev. 2007 Apr;54(1):34-66 [PMID: 17222914]
  3. Hum Brain Mapp. 2016 Jul;37(7):2398-406 [PMID: 27004598]
  4. Stroke. 1999 Jun;30(6):1190-5 [PMID: 10356098]
  5. Curr Pharm Des. 2020;26(34):4246-4260 [PMID: 32640953]
  6. ACS Appl Mater Interfaces. 2022 Jul 6;14(26):29491-29505 [PMID: 35731847]
  7. J Neural Transm (Vienna). 2016 Mar;123(3):323-8 [PMID: 26354101]
  8. Int Immunopharmacol. 2022 Jan;102:108393 [PMID: 34857480]
  9. Medicina (Kaunas). 2020 Jun 11;56(6): [PMID: 32545416]
  10. Naunyn Schmiedebergs Arch Pharmacol. 2018 Jun;391(6):613-625 [PMID: 29602953]
  11. Am J Physiol Gastrointest Liver Physiol. 2016 Nov 1;311(5):G974-G980 [PMID: 27686613]
  12. Exp Mol Pathol. 2020 Oct;116:104512 [PMID: 32745469]
  13. Ann Neurol. 2006 Jun;59(6):929-38 [PMID: 16673393]
  14. J Stroke Cerebrovasc Dis. 2022 Apr;31(4):106295 [PMID: 35093630]
  15. Biomed Pharmacother. 2022 Sep;153:113377 [PMID: 36076520]
  16. Cell Mol Life Sci. 2014 Oct;71(20):3987-4005 [PMID: 25008044]
  17. Diagnosis (Berl). 2022 Aug 18;9(4):499-507 [PMID: 35976169]
  18. Eur Rev Med Pharmacol Sci. 2018 Mar;22(5):1426-1436 [PMID: 29565504]
  19. Biochem Biophys Res Commun. 2021 Jan 22;537:36-42 [PMID: 33383562]
  20. Insect Sci. 2022 Jun;29(3):631-644 [PMID: 34232550]
  21. Pharmacol Res. 2021 Jan;163:105296 [PMID: 33220421]
  22. J Biosci Bioeng. 2021 Apr;131(4):396-404 [PMID: 33386278]
  23. Int J Mol Sci. 2020 Sep 14;21(18): [PMID: 32937836]
  24. Child Neuropsychol. 2014;20(5):557-82 [PMID: 24028185]
  25. Cell Death Differ. 2021 Jan;28(1):108-122 [PMID: 33162554]
  26. Oncol Lett. 2022 Jun 14;24(2):260 [PMID: 35765274]
  27. Int J Mol Sci. 2016 Oct 13;17(10): [PMID: 27754357]
  28. Clin Pract Cases Emerg Med. 2019 Jul 08;3(3):194-198 [PMID: 31404351]
  29. J Immunother Cancer. 2022 Jun;10(6): [PMID: 35738798]
  30. Biomed Pharmacother. 2022 Feb;146:112539 [PMID: 34923337]
  31. J Cell Commun Signal. 2021 Jun;15(2):283-290 [PMID: 33136287]
  32. J Physiol. 2011 Sep 1;589(17):4125-36 [PMID: 21646410]
  33. Cell Mol Life Sci. 2012 Jan;69(1):89-102 [PMID: 21833581]
  34. Biosens Bioelectron. 2022 Sep 15;212:114423 [PMID: 35671695]
  35. Cell Rep. 2020 Mar 24;30(12):4266-4280.e4 [PMID: 32209483]
  36. J Biol Chem. 2022 Oct;298(10):102429 [PMID: 36037970]
  37. J Pharmacol Exp Ther. 2023 Jan;384(1):123-132 [PMID: 35779862]
  38. Cancer Lett. 2021 Nov 1;520:26-37 [PMID: 34229059]
  39. Biochemistry. 2020 May 5;59(17):1701-1710 [PMID: 32298102]
  40. Eur J Neurosci. 2021 Feb;53(4):1171-1188 [PMID: 33340424]
  41. J Neuroophthalmol. 2022 Jul 12;: [PMID: 35830710]
  42. Mol Cancer Res. 2016 Aug;14(8):683-95 [PMID: 27141100]
  43. Curr Chem Genomics. 2010;4:43-9 [PMID: 21687560]
  44. Int J Mol Sci. 2020 Jul 15;21(14): [PMID: 32679729]
  45. Biochim Biophys Acta. 2008 Aug;1779(8):471-8 [PMID: 18194678]
  46. Nucleic Acids Res. 2020 Jan 8;48(D1):D127-D131 [PMID: 31504780]
  47. Brain Behav Immun. 2018 May;70:179-193 [PMID: 29499303]
  48. Burns Trauma. 2022 Jul 12;10:tkac032 [PMID: 35832307]
  49. Brain Res Bull. 2017 Sep;134:30-37 [PMID: 28625785]
  50. Oxid Med Cell Longev. 2021 Mar 9;2021:6631805 [PMID: 33777315]
  51. J Nanobiotechnology. 2021 Oct 2;19(1):304 [PMID: 34600530]
  52. Nat Rev Urol. 2022 Jun;19(6):367-380 [PMID: 35474107]
  53. Int J Biol Macromol. 2021 Mar 1;172:321-329 [PMID: 33454324]
  54. Neuropediatrics. 2014 Apr;45(2):120-2 [PMID: 24227208]
  55. CNS Neurol Disord Drug Targets. 2013 Aug;12(5):698-714 [PMID: 23469845]
  56. J Stroke Cerebrovasc Dis. 2019 Jan;28(1):1-9 [PMID: 30539753]
  57. Arch Biochem Biophys. 2020 Nov 30;695:108629 [PMID: 33068524]
  58. Biochem Biophys Res Commun. 2022 Apr 2;598:124-130 [PMID: 35158211]
  59. Int J Stroke. 2012 Jul;7(5):378-85 [PMID: 22712739]
  60. Exp Neurol. 2022 Nov;357:114180 [PMID: 35901974]
  61. Antioxidants (Basel). 2022 Apr 19;11(5): [PMID: 35624663]
  62. Front Pharmacol. 2021 Jul 12;12:669701 [PMID: 34326768]
  63. Lancet. 2018 Oct 6;392(10154):1269-1278 [PMID: 30319114]
  64. Mol Ther Nucleic Acids. 2019 Dec 6;18:681-695 [PMID: 31707205]
  65. Autophagy. 2017 Apr 3;13(4):715-729 [PMID: 28121493]
  66. Top Stroke Rehabil. 2018 Sep 13;:1-8 [PMID: 30213238]
  67. Biosensors (Basel). 2022 Jul 08;12(7): [PMID: 35884303]
  68. Eur Rev Med Pharmacol Sci. 2020 Feb;24(3):1524-1536 [PMID: 32096202]
  69. Acta Neurol Scand. 2019 Jul;140(1):3-8 [PMID: 30929256]
  70. Cell Metab. 2008 May;7(5):377-88 [PMID: 18460329]
  71. Int J Mol Sci. 2021 Jun 23;22(13): [PMID: 34201807]
  72. Biomed Res Int. 2021 Jul 6;2021:9933998 [PMID: 34307674]
  73. Cell Death Dis. 2019 Feb 4;10(2):97 [PMID: 30718467]
  74. Med Sci Monit. 2017 Apr 28;23:2042-2048 [PMID: 28453502]
  75. Int J Cardiol. 2016 Jan 15;203:418-9 [PMID: 26544065]

MeSH Term

Rats
Animals
MicroRNAs
AMP-Activated Protein Kinases
Reperfusion Injury
Neuroprotection
Oxygen
Apoptosis
Brain Ischemia

Chemicals

MicroRNAs
AMP-Activated Protein Kinases
Oxygen
mirn21 microRNA, rat

Word Cloud

Created with Highcharts 10.0.0OL-FS13miR-21-3ppeptideCI/ReffectsOGD/RCAMKK2neuroprotectiveischemia-reperfusionmechanismproteinkinase2therebyinhibitingfactorCerebralBACKGROUND:derivedOdorranalividacanalleviatecerebralinjuryalthoughspecificunderlyingremainsexploredOBJECTIVE:effectneural-protectiveexaminedMETHODS:studymultiplegenomesequencinganalysisdoubleluciferaseexperimentRT-qPCRWesternblottingusedexploreRESULTS:Showedover-expressionprotectiveoxygen-glucosedeprivation/re-oxygenation-damagedpheochromocytomaPC12cellsCI/R-injuredratsfoundtargetcalcium/calmodulin-dependentoverexpressioninhibitedexpressionphosphorylationdownstreamadenosine5'-monophosphateAMP-activatedAMPKtherapeuticInhibitionalsoantagonizedup-regulatednuclearerythroid2-relatedNrf-2abolishingantioxidantactivityCONCLUSION:resultsshowedalleviatedactivateCAMKK2/AMPK/Nrf-2axisAlleviatesIschemia-reperfusionInjuryInhibitingExpressionCAMKK2/AMPKpathwaymicroRNAoxidativestress

Similar Articles

Cited By (1)